/NVS
NVS Stock - Novartis AG
Healthcare|Drug Manufacturers - GeneralNYSE
$136.06+0.58%
+$0.79 (+0.58%) • Dec 19
62
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.76
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).37
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-6.7%upside
Target: $126.94
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NVS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$134.70 – $137.42
TARGET (TP)$127.00
STOP LOSS$125.18
RISK/REWARD1:-0.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.44
52W High$137.40
52W Low$96.91
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $51.72B | $46.66B | $43.46B | $43.97B | $49.90B |
| Gross Profit | $38.90B | $34.19B | $31.88B | $32.24B | $34.78B |
| Gross Margin | 75.2% | 73.3% | 73.4% | 73.3% | 69.7% |
| Operating Income | $14.54B | $9.77B | $7.95B | $10.06B | $10.15B |
| Net Income | $11.94B | $14.85B | $6.96B | $24.02B | $8.07B |
| Net Margin | 23.1% | 31.8% | 16.0% | 54.6% | 16.2% |
| EPS | $5.92 | $7.15 | $3.19 | $10.71 | $3.54 |
Company Overview
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
33%
Hold / Neutral
12
57%
Sell / Underperform
2
10%
Analyst Consensus🔴 Bearish
7 Bullish14 Neutral/Bearish
Price Targets
$120
Average Target
↓ 11.9% Downside
Now
$114
Low
$120
Average
$130
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 8th 2025 | JP Morgan | Upgrade | Overweight | - |
| December 3rd 2025 | Morgan Stanley | Upgrade | Overweight | - |
| November 25th 2025 | BofA Securities | Upgrade | Buy | - |
| September 12th 2025 | Goldman | Downgrade | Sell | $118 |
| August 8th 2025 | Morgan Stanley | Upgrade | Equal Weight | $123 |
| February 13th 2025 | UBS | Downgrade | Neutral | - |
| February 12th 2025 | Morgan Stanley | Initiation | Underweight | - |
| February 4th 2025 | Deutsche Bank | Upgrade | Buy | - |
| December 4th 2024 | HSBC Securities | Downgrade | Reduce | - |
| September 11th 2024 | BofA Securities | Downgrade | Neutral | $130← $135 |
| September 5th 2024 | Goldman | Downgrade | Neutral | - |
| September 3rd 2024 | Jefferies | Downgrade | Hold | - |
| July 19th 2024 | Deutsche Bank | Downgrade | Hold | - |
| May 30th 2024 | Goldman | Initiation | Buy | $120 |
| February 23rd 2024 | BMO Capital Markets | Initiation | Market Perform | $114 |
Earnings History & Surprises
NVSBeat Rate
83%
Last 18 quarters
Avg Surprise
+3.8%
EPS vs Estimate
Beats / Misses
15/3
Last 12 quarters
Latest EPS
$2.25
Q4 2025
EPS Surprise History
Q1 24
-6.7%
$1.53vs$1.64
Q2 24
+4.0%
$1.80vs$1.73
Q3 24
+4.2%
$1.97vs$1.89
Q4 24
+6.2%
$2.06vs$1.94
Q1 25
+10.0%
$1.98vs$1.80
Q2 25
+7.5%
$2.28vs$2.12
Q3 25
+1.7%
$2.42vs$2.38
Q4 25
-0.4%
$2.25vs$2.26
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 27, 2026 | — | — | — | — |
Q1 2026 | Jan 30, 2026 | $1.97 | — | — | — |
Q4 2025 | Oct 28, 2025 | $2.26 | $2.25 | -0.4% | ✗ MISS |
Q3 2025 | Jul 17, 2025 | $2.38 | $2.42 | +1.7% | ✓ BEAT |
Q2 2025 | Apr 29, 2025 | $2.12 | $2.28 | +7.5% | ✓ BEAT |
Q1 2025 | Jan 31, 2025 | $1.80 | $1.98 | +10.0% | ✓ BEAT |
Q4 2024 | Oct 29, 2024 | $1.94 | $2.06 | +6.2% | ✓ BEAT |
Q3 2024 | Jul 18, 2024 | $1.89 | $1.97 | +4.2% | ✓ BEAT |
Q2 2024 | Apr 23, 2024 | $1.73 | $1.80 | +4.0% | ✓ BEAT |
Q1 2024 | Jan 31, 2024 | $1.64 | $1.53 | -6.7% | ✗ MISS |
Q4 2023 | Oct 24, 2023 | $1.70 | $1.74 | +2.4% | ✓ BEAT |
Q3 2023 | Jul 18, 2023 | $1.68 | $1.83 | +8.9% | ✓ BEAT |
Q2 2023 | Apr 25, 2023 | $1.55 | $1.71 | +10.3% | ✓ BEAT |
Q1 2023 | Feb 1, 2023 | $1.42 | $1.51 | +6.3% | ✓ BEAT |
Q4 2022 | Oct 25, 2022 | $1.57 | $1.58 | +0.6% | ✓ BEAT |
Q3 2022 | Jul 19, 2022 | $1.51 | $1.56 | +3.3% | ✓ BEAT |
Q2 2022 | Apr 26, 2022 | $1.44 | $1.46 | +1.4% | ✓ BEAT |
Q1 2022 | Feb 2, 2022 | $1.44 | $1.40 | -2.8% | ✗ MISS |
Q4 2021 | Oct 26, 2021 | $1.65 | $1.71 | +3.6% | ✓ BEAT |
Q3 2021 | Jul 21, 2021 | $1.53 | $1.66 | +8.5% | ✓ BEAT |
Latest News
President Trump Says The 3 Of The 17 Pharmaceutical Companies Who Have Not Agreed Are Coming In Next Week
➖ NeutralBenzinga•Dec 19, 2025, 07:30 PM•Also: , ,
Senior Administration Official Says President Trump To Announce Deals With Nine Pharmaceutical Companies To Reduce Drug Prices; Deals Are With Amgen, Bristol Myers Squibb, Roche's GenenTech, Gilead, GSK, Merck, Novartis, Sanofi And Boehringer Ingelheim; Each Manufacturer Agrees To Reduce Prices On Majority Of Medications Sold Through Medicaid; Companies Commit To $150B In New Investment In Manufacturing And R&D In U.S.
📈 PositiveBenzinga•Dec 19, 2025, 07:20 PM•Also: , ,
Trump Administration Proposes Rule Banning Medicaid And CHIP From Paying For Gender Affirming Care
➖ NeutralBenzinga•Dec 18, 2025, 04:27 PM•Also: , ,
Salesforce shares are trading higher after BTIG initiated coverage on the stock with a Buy rating and announced a $335 price target. The company announced that its Agentforce Life Sciences has been selected by Novartis to drive more personalized customer engagement globally.
📈 PositiveBenzinga•Dec 17, 2025, 06:22 PM•Also:
'Novartis, Roche Near US Drug Price Deal in Easing of Swiss Trade Tensions'- Bloomberg
📈 PositiveBenzinga•Dec 17, 2025, 06:06 PM•Also:
Novartis To Use Salesforce's Agentforce Life Sciences For Customer Engagement
📈 PositiveBenzinga•Dec 17, 2025, 02:02 PM•Also:
China Isotope & Radiation Enters Strategic Commercial Cooperation With Novartis For Pluvicto Prostate Cancer Therapy In China
📈 PositiveBenzinga•Dec 15, 2025, 01:17 PM
Novartis Breaks Ground On 700K-Square-Foot Manufacturing Hub In North Carolina, Expected To Create 700 Jobs By 2030
📈 PositiveBenzinga•Dec 12, 2025, 12:09 PM
JP Morgan Upgrades Novartis to Overweight
📈 PositiveBenzinga•Dec 8, 2025, 01:14 PM
Novartis Receives FDA Approval For Itvisma, The Only Gene Replacement Therapy For Children Two Years And Older, Teens, And Adults With Spinal Muscular Atrophy
📈 PositiveBenzinga•Nov 24, 2025, 11:06 PM
Novartis Announces Plans To Build Flagship Manufacturing Hub In North Carolina
📈 PositiveBenzinga•Nov 19, 2025, 05:34 PM
Novartis Opens New Production Site In Carlsbad, California
📈 PositiveBenzinga•Nov 10, 2025, 02:32 PM
Key deals this week: Qorvo, Chewy, Sotherly Hotels, Novartis, CSG Systems, and more
➖ NeutralSeeking Alpha•Nov 1, 2025, 07:15 PM•Also: , ,
Novartis Ianalumab First Drug To Reduce Disease Activity And Patient Burden In Sjögren's Disease Phase III Trials
📈 PositiveBenzinga•Oct 29, 2025, 02:40 PM
Novartis shares are trading lower after the company reported Q3 revenue below estimates.
📉 NegativeBenzinga•Oct 28, 2025, 06:01 PM
Novartis Reaffirmed Its Full-Year 2025 Guidance, Maintaining Expectations For High Single-Digit Sales Growth And Low-Teens Core Operating Income Growth.
📈 PositiveBenzinga•Oct 28, 2025, 07:03 AM
Novartis Q3 Adj. EPS $2.25, Inline, Sales $13.909B Miss $14.105B Estimate
📉 NegativeBenzinga•Oct 28, 2025, 06:56 AM
Dyne Therapeutics shares are trading higher after Novartis announced the acquisition of Avidity Biosciences, which also develops therapies for neuromuscular disease.
📈 PositiveBenzinga•Oct 27, 2025, 04:48 PM•Also: ,
Avidity Biosciences shares are trading higher after Novartis announced it will acquire the company for $72 per share in cash.
📈 PositiveBenzinga•Oct 27, 2025, 01:43 PM•Also:
Avidity stock surges on $12B Novartis deal
📈 PositiveSeeking Alpha•Oct 27, 2025, 08:35 AM•Also:
Frequently Asked Questions about NVS
What is NVS's current stock price?
Novartis AG (NVS) is currently trading at $136.06 per share. The stock has moved +0.58% today.
What is the analyst price target for NVS?
The average analyst price target for NVS is $127.00, based on 1 analyst.
What sector is Novartis AG in?
Novartis AG operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the NYSE exchange.
What is NVS's market cap?
Novartis AG has a market capitalization of $266.24 billion, making it a mega-cap company.
Does NVS pay dividends?
No, Novartis AG does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABBV
AbbVie Inc.
$226.72
Mkt Cap: $400.7B
AZN
AstraZeneca PLC
$91.36
Mkt Cap: $283.3B
BAYRY
Bayer AG
$10.45
Mkt Cap: $41.1B
BMY
Bristol-Myers Squibb Company
$54.19
Mkt Cap: $110.3B
GILD
Gilead Sciences, Inc.
$124.29
Mkt Cap: $154.2B
GSK
GSK plc
$48.61
Mkt Cap: $98.8B
JNJ
Johnson & Johnson
$206.37
Mkt Cap: $497.2B
LLY
Eli Lilly and Company
$1071.44
Mkt Cap: $962.5B
MRK
Merck & Co., Inc.
$101.09
Mkt Cap: $254.1B
PFE
Pfizer Inc.
$25.20
Mkt Cap: $143.3B
Explore stocks similar to NVS for comparison